PURPOSE: We aimed to evaluate the expression of the human anterior gradient-2 (AGR2) in breast cancer on RNA and protein level and to correlate it with clinicopathologic data, including patient survival. EXPERIMENTAL DESIGN: AGR2 mRNA expression was assessed by reverse transcription-PCR in 25 breast cancer samples and normal tissues. A polyclonal rabbit AGR antiserum was used for immunohistochemistry on 155 clinicopathologically characterized cases. Statistical analyses were applied to test for prognostic and diagnostic associations. RESULTS: Immunohistochemical detection of AGR2 was statistically significantly associated with positive estrogen receptor status and lower tumor grade. AGR2-positive tumors showed significantly longer overall survival times in univariate analyses. For the subgroup of nodal-negative tumors, an independent prognostic value of AGR2 was found. CONCLUSIONS: The expression of AGR2 in breast cancer is strongly associated with markers of tumor differentiation (estrogen receptor positivity, lower tumor grade). A prognostic effect of AGR2 for overall survival could be shown, which became independently significant for the group of nodal-negative tumors.
PURPOSE: We aimed to evaluate the expression of the humananterior gradient-2 (AGR2) in breast cancer on RNA and protein level and to correlate it with clinicopathologic data, including patient survival. EXPERIMENTAL DESIGN:AGR2 mRNA expression was assessed by reverse transcription-PCR in 25 breast cancer samples and normal tissues. A polyclonal rabbit AGR antiserum was used for immunohistochemistry on 155 clinicopathologically characterized cases. Statistical analyses were applied to test for prognostic and diagnostic associations. RESULTS: Immunohistochemical detection of AGR2 was statistically significantly associated with positive estrogen receptor status and lower tumor grade. AGR2-positive tumors showed significantly longer overall survival times in univariate analyses. For the subgroup of nodal-negative tumors, an independent prognostic value of AGR2 was found. CONCLUSIONS: The expression of AGR2 in breast cancer is strongly associated with markers of tumor differentiation (estrogen receptor positivity, lower tumor grade). A prognostic effect of AGR2 for overall survival could be shown, which became independently significant for the group of nodal-negative tumors.
Authors: Fang Zhao; Robert Edwards; Diana Dizon; Kambiz Afrasiabi; Jennifer R Mastroianni; Mikhail Geyfman; André J Ouellette; Bogi Andersen; Steven M Lipkin Journal: Dev Biol Date: 2009-12-16 Impact factor: 3.582
Authors: Suman Verma; Michael L Salmans; Mikhail Geyfman; Hong Wang; Zhengquan Yu; Zhongxian Lu; Fang Zhao; Steven M Lipkin; Bogi Andersen Journal: Dev Biol Date: 2012-07-20 Impact factor: 3.582
Authors: Yuexing Zhang; Douglas Linn; Zhenqiu Liu; Jonathan Melamed; Fabio Tavora; Charles Y Young; Angelika M Burger; Anne W Hamburger Journal: Mol Cancer Ther Date: 2008-10 Impact factor: 6.261
Authors: Dong L Barraclough; Angela Platt-Higgins; Suzete de Silva Rudland; Roger Barraclough; John Winstanley; Christopher R West; Philip S Rudland Journal: Am J Pathol Date: 2009-10-15 Impact factor: 4.307
Authors: Ru Chen; Sheng Pan; Xiaobo Duan; Brad H Nelson; Rob A Sahota; Sarah de Rham; Richard A Kozarek; Martin McIntosh; Teresa A Brentnall Journal: Mol Cancer Date: 2010-06-15 Impact factor: 27.401